Cartesian Therapeutics, Inc. (RNAC) Tuesday announced positive updated data from the Phase 2b trial of Descartes-08 in people with myasthenia gravis (MG), an autoimmune disease that causes weakness in the voluntary muscles. The company's shares were up more than 5 percent in pre-market.
As previously announced, the trial had met its primary goal.
New data from the Phase 2b study showed that Descartes-08 provided deep and durable improvements over time for MG patients, with 5.5 reduction in MG Activities of Daily Living (MG-ADL) at Month 4. Durable responses were observed through Month 12, with 80 percent of participants showed a reduction in MG-ADL score of at least 2 points.
A Phase 3 study of Descartes-08, dubbed AURORA, is planned to begin in the first half of 2025.
Cartesian Therapeutics stock had closed at $19.57, up 3.93 percent on Monday. It has traded in the range of $11.66 - $41.87 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.